会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Cyanopyrroles
    • 青色
    • US08476262B2
    • 2013-07-02
    • US12915211
    • 2010-10-29
    • Mark A. CollinsValerie A. MacknerJay E. WrobelLin ZhiTodd K. JonesChristopher M. TegleyJames P. Edwards
    • Mark A. CollinsValerie A. MacknerJay E. WrobelLin ZhiTodd K. JonesChristopher M. TegleyJames P. Edwards
    • A61K31/535
    • C07D403/04A61K31/405A61K31/5415C07D413/04
    • This invention provides a progesterone receptor antagonist of formula 1 having the structure wherein, T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—; n=1-5; p=1-4; q=1-4; R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA; RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R5 is hydrogen, alkyl, or substituted alkyl; R6 is hydrogen, alkyl, substituted alkyl, or CORB; RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R7 is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.
    • 本发明提供具有以下结构的式1的孕酮受体拮抗剂,其中T为O,S或不存在; R 1和R 2各自独立地为氢,烷基,取代的烷基; 或R 1和R 2一起形成环,并且一起含有-CH 2(CH 2)n CH 2 - , - CH 2 CH 2 CH 2 CH 2 CH 2 - , - O(CH 2)p CH 2 - , - O(CH 2)q O - , - CH 2 CH 2 OCH 2 CH 2 - 或-CH 2 CH 2 NR 7 CH 2 CH 2 - n = 1-5; p = 1-4; q = 1-4; R3是氢,OH,NH2,烷基,取代的烷基,烯基,取代的烯基,炔基,取代的炔基或CORA; RA是氢,烷基,取代的烷基,烷氧基,取代的烷氧基,氨基烷基或取代的氨基烷基; R4是氢,卤素,CN,NH2,烷基,取代的烷基,烷氧基,取代的烷氧基,氨基烷基或取代的氨基烷基; R5是氢,烷基或取代的烷基; R6是氢,烷基,取代的烷基或CORB; RB是氢,烷基,取代的烷基,烷氧基,取代的烷氧基,氨基烷基或取代的氨基烷基; R7是氢或烷基; 或其药学上可接受的盐。
    • 10. 发明申请
    • Cyanopyrroles
    • 青色
    • US20110039839A1
    • 2011-02-17
    • US12915211
    • 2010-10-29
    • Mark A. CollinsValerie A. MacknerJay E. WrobelLin ZhiTodd K. JonesJames P. EdwardsChristopher M. Tegley
    • Mark A. CollinsValerie A. MacknerJay E. WrobelLin ZhiTodd K. JonesJames P. EdwardsChristopher M. Tegley
    • A61K31/536A61K31/404A61P15/18A61P35/00
    • C07D403/04A61K31/405A61K31/5415C07D413/04
    • This invention provides a progesterone receptor antagonist of formula 1 having the structure wherein, T is O, S, or absent; R1, and R2 are each, independently, hydrogen, alkyl, substituted alkyl; or R1 and R2 are taken together form a ring and together contain —CH2(CH2)nCH2—, —CH2CH2CMe2CH2CH2—, —O(CH2)pCH2—, —O(CH2)qO—, —CH2CH2OCH2CH2—, or —CH2CH2NR7CH2CH2—; n=1-5; p=1-4; q=1-4; R3 is hydrogen, OH, NH2, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, or CORA; RA is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R4 is hydrogen, halogen, CN, NH2, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R5 is hydrogen, alkyl, or substituted alkyl; R6 is hydrogen, alkyl, substituted alkyl, or CORB; RB is hydrogen, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aminoalkyl, or substituted aminoalkyl; R7 is hydrogen or alkyl; or a pharmaceutically acceptable salt thereof.
    • 本发明提供具有以下结构的式1的孕酮受体拮抗剂,其中T为O,S或不存在; R 1和R 2各自独立地为氢,烷基,取代的烷基; 或R 1和R 2一起形成环,并且一起含有-CH 2(CH 2)n CH 2 - , - CH 2 CH 2 CH 2 CH 2 CH 2 - , - O(CH 2)p CH 2 - , - O(CH 2)q O - , - CH 2 CH 2 OCH 2 CH 2 - 或-CH 2 CH 2 NR 7 CH 2 CH 2 - n = 1-5; p = 1-4; q = 1-4; R3是氢,OH,NH2,烷基,取代的烷基,烯基,取代的烯基,炔基,取代的炔基或CORA; RA是氢,烷基,取代的烷基,烷氧基,取代的烷氧基,氨基烷基或取代的氨基烷基; R4是氢,卤素,CN,NH2,烷基,取代的烷基,烷氧基,取代的烷氧基,氨基烷基或取代的氨基烷基; R5是氢,烷基或取代的烷基; R6是氢,烷基,取代的烷基或CORB; RB是氢,烷基,取代的烷基,烷氧基,取代的烷氧基,氨基烷基或取代的氨基烷基; R7是氢或烷基; 或其药学上可接受的盐。